N
NERV icon

Nuveen’s Minerva Neurosciences NERV Stock Holding History

Nuveen’s Portfolio NERV Stock Details NERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-15,335
Closed -$1.65M – 3481
2021
Q1 		$1.65M Sell
15,335
-406
-3% -$10.1K ﹤0.01% 2701
2020
Q4 		$1.7M Buy
15,741
+141
+0.9% +$3.55K ﹤0.01% 2587
2020
Q3 		$1.68M Sell
15,600
-16,607
-52% -$449K ﹤0.01% 2466
2020
Q2 		$3.47M Sell
32,207
-18,346
-36% -$1.08M ﹤0.01% 2086
2020
Q1 		$2.43M Buy
50,553
+36,211
+252% +$2.18M ﹤0.01% 2094
2019
Q4 		$815K Sell
14,342
-11,534
-45% -$509K ﹤0.01% 2754
2019
Q3 		$1.6M Buy
25,876
+825
+3% +$46.7K ﹤0.01% 2500
2019
Q2 		$1.13M Buy
+25,051
New +$1.25M ﹤0.01% 2686

Other funds holding NERV

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Nuveen's NERV Position: Q2 2021 in Review

Nuveen sold out of Minerva Neurosciences (NERV) in Q2 2021, closing a stake of 15,335 shares — an estimated $1.65M sold.

Nuveen first reported a position in NERV in Q2 2019 and held it in 8 quarters. The position peaked at $3.47M in Q2 2020. 68 funds tracked by Wall St. Rank hold NERV as of Q2 2021.

  • Nuveen reported no remaining Minerva Neurosciences position as of Q2 2021 after selling out during the quarter.
  • Nuveen sold 15,335 Minerva Neurosciences shares in Q2 2021, an estimated $1.65M.
  • Nuveen first reported a position in Minerva Neurosciences in Q2 2019 and held it in 8 quarters.
  • Nuveen's Minerva Neurosciences position peaked at $3.47M in Q2 2020.
  • 68 funds tracked by Wall St. Rank held Minerva Neurosciences as of Q2 2021.

Based on Nuveen's 13F filing for Q2 2021, filed 16 Aug 2021.